Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Remifentanil · Ultiva, GI 87084X

Small molecule · Agonist of mu-opioid receptor (OPRM1) · developed by Mylan Institutional

Approved FDA, Jul 1996
1 Registered trials

What is Remifentanil?

Remifentanil is a short-acting mu-opioid receptor agonist with rapid onset and offset, cleared by nonspecific blood and tissue esterases. It is used intravenously as an analgesic during general anesthesia, in the postoperative period, and during monitored anesthesia care, and has been studied for pain relief in labour.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ultiva, GI 87084X
Drug type
Small molecule
Targets
mu-opioid receptor (OPRM1)
Mechanism
Agonist of mu-opioid receptor (OPRM1)
Pathways
opioid receptor signaling
Therapy area
Oncology
Developer
Mylan Institutional
In trials of
STOK
FDA status
Approved as Ultiva (July 12, 1996), NDA020630 · FDA label
UNII
P10582JYYK

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 15, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02179294 Phase 4 Pain Relief in Labour Completed STOK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pain Relief in Labour

Other drugs acting on OPRM1

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.